Publications
461 publications
- Date
- Relevance
-
Rivaroxaban (Xarelto) for the indication 'treatment of pulmonary embolism'
The WAR has approved a pharmacotherapeutic report for the medicine rivaroxaban (Xarelto®) 15 mg tablet for oral use. In ...
-
Catumaxomab (Removab) for the indication ‘malignant ascites’
The most important effect of catumaxomab in clinical research is a statistically significant 35-day extension in ‘puncture-free ...
-
Tapentadol (Palexia Retard) for the indication severe chronic pain
The therapeutic value of tapentadol for the treatment of severe chronic pain in adults who can only be treated with opioid ...
-
Mirabegron (Betmiga) for the indication overactive bladder syndrome
The WAR approved the pharmacotherapeutic report of the medicine mirabegron (Betmiga). Its therapeutic value was determined via ...
-
Coronary Heart Disease Package Scan
In a package scan we analyse the adequacy and accessibility of the package of insured care for a particular disease. Does the ...
-
Intestinal transplant
The National Health Care Institute concludes that intestinal transplants in patients with intestinal failure who have persistent ...
-
Depression Package Scan
In 2009 there were 555,000 people suffering from depression in the Netherlands. The degree to which people with a depression ...
-
Zostavax for the prevention of Herpes Zoster and Postherpetic Neuralgia
The primary efficacy outcome of the SPS is vaccine efficacy for the burden of illness (BOI), a composite endpoint affected by the ...
-
Trastuzuma (Herceptin) for HER2-positive early breast cancer
Recommendation by the National Health Care Institute [Zorginstituut Nederland] dated 10-09-2013, based on a re-evaluation by the ...
-
COPD Package Scan
In 2007 there were almost 324,000 people with COPD (Chronic Obstructive Pulmonary Disease) in the Netherlands. The quality of ...